Justice Department, Drug Enforcement Administration Briefing 2025-06-02
Estimated reading time: 4 minutes
1. Bulk Manufacturer of Controlled Substances Application: Veranova, L.P.
Sub: Justice Department, Drug Enforcement Administration
Content: Veranova, L.P. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
2. Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: ANI Pharmaceuticals Inc has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
3. Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; Electronic Applications for the Attorney General’s Honors Program and the Summer Law Intern Program (HP/SLIP)
Sub: Justice Department
Content: The Office of Attorney Recruitment and Management, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the Federal Register on March 24, 2025, allowing a 60-day comment period.
4. Privacy Act of 1974; Systems of Records
Sub: Justice Department
Content: Pursuant to the Privacy Act of 1974 and Office of Management and Budget (OMB) Circular No. A-108, notice is hereby given that the Justice Management Division (JMD), a component within the United States Department of Justice (DOJ or Department), proposes to modify the system of records titled Security Monitoring and Analytics Service Records, JUSTICE/JMD-026, updating the capabilities and offerings included in it.
Legal Disclaimer
This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
